Jump to content

SLA - SILK LASER AUSTRALIA LIMITED


ShareCafe

Recommended Posts

  • Replies 43.2k
  • Created
  • Last Reply

Top Posters In This Topic

  • chiller

    2097

  • diana

    1910

  • Livas1

    4166

  • jezzabot

    2629

Top Posters In This Topic

Posted Images

 

News Alert for: SLA

Tiny biotech set to de-liver

Herald Sun

A SMALL Melbourne biotechnology company has achieved a major breakthrough after getting pharmaceutical registration in Russia. Solagran will today announce that its drug Ropren can be prescribed for liver disease in Russia. That means ...

 

 

Email Article to a Friend

Full Article...

 

 

Edit subscriptions here

Unsubscribe

Link to comment
Share on other sites

In reply to: Lizard on Wednesday 18/07/07 06:36am

A great article Lizard...a complete absence of negatives in it, quirky not mentioned, even polyprenols are mentioned before pine needles!!!

 

Yes it reads like a script from a new PR campaign...

Link to comment
Share on other sites

In reply to: nifty49 on Wednesday 18/07/07 09:07am

Nifty,

 

Denis will be on BRR around 2 pm on the day Solagran make an announcement, could be today but nothing out yet.

 

Manoli,

 

My apologies, I should have remembered how to spell Schultheiss, I drank enough http://www.sharescene.com/html/emoticons/wink.gif

 

 

Cheers Charles

Link to comment
Share on other sites

John Beveridge

 

July 18, 2007 12:00am

A SMALL Melbourne biotechnology company has achieved a major breakthrough after getting pharmaceutical registration in Russia.

 

Solagran will today announce that its drug Ropren can be prescribed for liver disease in Russia.

 

That means the drug should start to sell in Russia this year, with the next development steps being to seek approval in the rest of Europe and the United States.

 

Trials have shown Ropren and its active ingredient Bioeffective R is highly effective in treating chronic liver diseases including various forms of hepatitis and cirrhosis.

 

Further trials both in Russia and Melbourne have also shown Ropren could also be effective in normalising blood lipids such as cholesterol and in treating and preventing neurodegenerative conditions such as Alzheimers and Parkinson's disease.

 

Solagran shares have been in a trading halt since Monday pending today's announcement.

 

They have traded from a low of 17 in September last year to a high of $1.55 in May this year.

 

Solagran has already announced that it is dramatically ramping up European production of Ropren to cater for the estimated 10 million people with liver disease in Russia.

 

Unlike most drugs, the active ingredient in Ropren is a natural compound known as a polyprenol that is isolated from green conifer needles.

 

It was first developed in Russia by Professor Victor

Go SLA and the Doggies http://www.sharescene.com/html/emoticons/wub.gif

 

 

 

Link to comment
Share on other sites

I do not think it would break the rules for for SLA to 'leak' to the media during the TH as long as the market is fully informed when the TH is lifted. Therefore it is possible the draft for the article was written by SLA http://www.sharescene.com/html/emoticons/wink.gif
Link to comment
Share on other sites

In reply to: AtMarket on Wednesday 18/07/07 09:29am

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¦ and no mention of it being the first pharmaceutical approved in Russia for 20 years?

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...